IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: Phase I/II clinical trials on relapsed cutaneous T-cell lymphoma (CTCL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s disease (HD) patients with confirmed expression of either p55 or p75 IL-2R subunits verified the activity and safety of DAB389IL-2.